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Abstract: Women that are positive for an ovarian abnormality in a clinical setting can have either a
malignancy or a benign tumor with probability favoring the benign alternative. Accelerating the
abnormality to surgery will result in a high number of unnecessary procedures that will place cost
burdens on the individual and the health delivery system. Surveillance using serial ultrasonography
is a reasonable alternative that can be used to discover if changes in the ovarian abnormality will occur
that favor either a malignant or benign interpretation. Several ovarian cancer screening trials have
had extensive experiences with changes in subclinical ovarian abnormalities in normal women that
can define growth, stability or resolution and give some idea of the time frame over which changes
occur. The present report examines these experiences and relates them to the current understanding
of ovarian cancer ontology, presenting arguments related to the benefits of surveillance.
Keywords: ovary; cancer; screening; monitoring; surveillance; serial ultrasonography
1. Introduction
Ovarian cancer is the deadliest cancer that women face, causing more deaths than any other
cancer of the female reproductive system [1]. However, the prevalence of ovarian cancer is low,
responsible for only about 3% of all cancers in women [2] and accounting for a lifetime risk of 1.3%
(1 in 75) [3]. Transvaginal ultrasound (TVS) has been widely recognized as the first line for evaluating
adnexal masses presenting both low risk and low cost. Prospective ovarian cancer screening trials
have utilized TVS to detect early stage malignancies. The five-year survival rate for women diagnosed
with stage I ovarian cancer has been reported to be as high as 95% [4,5] in contrast to only 30% for
women with stage III disease [6]. While large prospective screening trials have focused on how best
to identify malignancies in asymptomatic women in the general population, adnexal masses are
commonly identified by ultrasound ordered for a wide variety of indications in routine clinical practice
even when a patient does not present with relevant symptoms. While the US Preventive Services
Task Force (USPSTF) has recommended against population screening for ovarian cancer [7], many
women undergo ultrasound for various symptoms. This paper reviews recent prospective ovarian
cancer screening trial findings for clinical application on how women with adnexal masses, found by
ultrasound, for various reasons other than for screening purposes, should be managed and followed.
Ovarian cysts are often observed sonographically even in post-menopausal women with a
reported incidence rate of up to 21% [8]. The question of how best to manage these masses has
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been the subject of much interest and debate among clinicians including obstetric gynecologists,
primary care physicians, radiologists and gynecology oncologists. Several reports have asserted that
resected ovarian cysts do not contain malignancy [9–11], but that if left unmonitored, ovarian cysts can
progress to ovarian cancers [12,13]. Therefore, all ovarian cysts may present some source of concern.
Historically, this concern has led to a conundrum among radiologists and clinicians. Should these
cysts be monitored (how frequently and for how long) or should ovarian cysts be managed operatively
at the risk of potential harm from surgical complications and medical expenses?
In 2010, a consensus panel of the Society of Radiologists in Ultrasound (SRU) that was composed
of 19 experts in radiology, obstetric gynecology, and gynecology oncology, as well as pathology
released a recommendation regarding the management of adnexal masses found sonographically
in asymptomatic women [14]. The panel analyzed literature available at the time of the conference
(October 2009) and strategies in clinical practice with the goal of reaching a consensus on: (1) which
masses might not require follow-up, (2) which masses would need imaging follow-up, as well as when
follow-up evaluation should occur, and (3) which masses should warrant referral to a gynecologic
oncologist for surgical evaluation. The consensus agreed that it is reasonable to perform annual
ultrasound follow-up of cysts larger than 5 cm in premenopausal women and those larger than 1 cm in
postmenopausal women, although such cysts are unlikely to be malignant [14]. A recent expert review
suggested that low risk abnormalities can undergo an initial three-month follow-up with those that
remain stable or decreasing in size being examined every 12 months for five years [15].
Since the SRU guidelines from 2010 [14], differences over how best to manage adnexal masses
persisted and were recently addressed by the first international consensus conference on adnexal
masses [15]. This panel included representatives of societies in the fields of gynecology, gynecologic
oncology, radiology and pathology and clinicians from Europe, Canada and the United States. While
many of the adnexal masses are benign appearing (i.e., simple cysts or hemorrhagic cysts), for many
more, it is not clear whether the mass may contain foci of malignancy and consequently are classified
as indeterminate. As a clarification of terminology, “simple cysts” and “unilocular cysts” are the same
and are characterized as being anechoic structures that are absent papillae, solid areas and septa
(complete or incomplete). The low prevalence of ovarian cancer (3%) [2] establishes the likelihood that
most ovarian cysts are benign yet cysts cannot be dismissed because they occur with a high incidence
rate (21–35%) [8]. Some cysts are not simple and include morphologic elements that can demonstrate
multiseptations or small solid nodules. No specific guideline had been established for indeterminate
masses by the SRU consensus due to the fact that data analyzing long-term follow up of adnexal
masses at the time was insufficient. The SRU stated that “as research continues, the recommendations
regarding management of adnexal cysts may vary”. The present review examines the evidence
from recent research in histopathology of ovarian cancer types, ovarian cancer screening trials and
ultrasound morphology of adnexal masses to establish a framework for surveillance of these masses.
2. Type 1 and Type 2 Ovarian Cancers Found in Ultrasound Imaging
Currently, ovarian cancers now include two distinct types of malignancy: Type 1 or 2 based
on histologic pathogenesis, molecular alterations and clinical progression (Table 1). Type 1 ovarian
cancers include low grade serous carcinoma, endometrioid carcinoma, and clear cell carcinoma.
Type 1 ovarian cancers demonstrate a step-wise progression originating from a benign precursor
or borderline tumor or endometriosis [16–18]. For example, low grade serous carcinomas may
arise via transformation of benign and borderline serous tumors that are thought to be derived
from inclusion cysts originating from the ovarian surface or tubal epithelium. This progression is
analogous to the adenoma-to-carcinoma sequence seen in colorectal carcinoma pathogenesis or the
hyperplasia-to-carcinoma sequence in endometrioid carcinoma of the endometrium [19].
In contrast, Type 2 ovarian cancers are highly aggressive and include high grade serous, high grade
endometrioid and undifferentiated carcinomas, as well as malignant mixed mesodermal carcinomas,
usually presenting at an advanced stage [17,19,20]. Type 2 ovarian cancers often have TP53 mutations
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but rarely have mutations that are associated with Type 1 ovarian malignancies [17,20]. Some Type 2
ovarian cancers (in particular, high grade serous carcinoma) are associated with BRCA (BReast CAncer
susceptibility gene) inactivation [21]. Compelling evidence indicates that these malignancies may
originate from the epithelium of the fimbrial portion of the fallopian tube as serous tubal intraepithelial
carcinomas (STIC) [22–32]. Finally, some high grade serous carcinomas have been reported to develop
from transformation of serous borderline tumors or low grade Type 1 serous carcinomas [17–20]. While
pathogenesis may differ, the morphology of the high-grade serous carcinomas that develop in the
Type 2 pathway is similar to high-grade serous carcinomas that are transformed from Type 1 tumors
with shared clinical behaviors [17]. Using this paradigm, a stratified treatment plan can be devised.
However, currently there is no prospective means that differentiates between the subtypes of ovarian
cancer based on ultrasound imaging. Based on recent ovarian cancer screening results, abnormalities
with lesser degrees of morphologic complexity may harbor micro foci of ovarian cancer indicating
that a wide spectrum of abnormal morphology should be considered for ultrasound follow up and
active surveillance.
Table 1. Summary of Type 1 and Type 2 ovarian carcinomas.
Tumor Type Type 1 Tumors Type 2 Tumors
Behavior Indolent Aggressive
Diagnosis at Early Stage Advanced Stage
Survival Rate at 5 years About 55% About 30%
Type/Precursor
-Endometrioid
carcinoma/Endometriosis
-Clear cell carcinoma/Endometriosis
Mucinous carcinoma/Mucinous
Cystadenoma, Endometriosis, Teratoma,
-Brenner Tumor, and Mucinous
borderline tumor
-Low grade serous carcinoma/Serous
cystadenoma, Adenofibroma, Atypical
proliferative serous tumor, Mullerian
epithelial cyst
-Transitional cell carcinoma or
Malignant Brenner tumor/
Brenner tumor
-High grade serous
carcinoma/Probably de novo
starting at the tubo, ovarian
surface epithelium, serous tubal
intraepithelial carcinomas (STIC)
or ovarian hilum stem cell
-Undifferentiated carcinoma?
-Malignant mixed carcinoma?
2.1. Summary of Information from Recent Prospective Ovarian Cancer Screening Trials
There have been four large prospective ovarian cancer screening trials utilizing ultrasound in
asymptomatic women [5,33–35]. The first randomized control trial in the US was the Prostate, Lung,
Colorectal and Ovarian Cancer Screening (PLCO) Trial, a randomized controlled trial (RCT) of 68,616
women aged 55 to 74 of whom 30,630 underwent screening between 1993 and 2007 [34]. Women
were screened using serum CA-125 (cancer antigen 125) at a cut-off of ≥35 kU/L and transvaginal
ultrasound (TVS) for four years followed by CA-125 alone for an additional two years. Endpoint
analysis showed that screening with the combination of CA-125 and transvaginal ultrasound had no
mortality benefit compared to the unscreened control group [34]. Importantly, in the PLCO study,
surgical decisions were made on the basis of a single ultrasound exam and an absolute CA-125 level of
35 units/mL. More importantly, the PLCO trial had no uniform evaluation and treatment algorithm
for patients with screen-detected adnexal masses so that women identified in the screening arm could
be treated up to nine months after ultrasound detection, allowing their disease to progress to later
stages during this time.
In the multicenter prospective randomized Shizuoka Cohort Study of Ovarian Cancer Screening
(SCSOCS) trial in Japan [33], conducted between 1985 and 1999, asymptomatic postmenopausal women
were assigned either to a screening arm (n = 41,688) or to a control arm (n = 40,799). Furthermore,
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63% of ovarian cancers detected by screening were stage I disease versus 38% in the control arm.
Importantly, optimal tumor debulking was achieved more often in women whose ovarian cancer was
detected by screening [33]. Assessment of ovarian cancer specific survival was not completed in the
SCSOCS trial.
More recent studies have been published with a screening strategy that improves on using a
single ultrasound exam or a single CA-125 value at 35 units/mL, an approach that did not achieve an
acceptable positive predictive value (PPV) in the PLCO trial [34]. These strategies include the use of
serial ultrasound instead of a single ultrasound exam dictating the surgical decision and the utilization
of multimodalities keying on changes in serial CA 125 determinations. The University of Kentucky
Ovarian Cancer Screening Trial utilized a prospective single arm that focused on annual ultrasound
screening study of 25,327 women from 1987 to 2012 [36]. In the Kentucky study, serial ultrasound follow
up of the 6807 women with ovarian abnormalities displaying varying ultrasonographic morphologic
features resulted in a 304% improved PPV from 8.1% to 25% and reduced unnecessary surgery on
benign tumors [36]. Importantly, this study found that women in the screening group had a higher
rate of earlier stage cancer discovery (68% stage I or II disease) than the unscreened comparison group
(27% stage I or II, p < 0.01) [36–38]. Overall five-year survival of women who had epithelial ovarian
cancer (EOC) found during the serial ultrasound follow up including false negative cancers was
74.8% ± 6.6% compared to 53.7% ± 2.3% for women who were clinically detected (p < 0.01) [37,38].
Using the serial ultrasound approach, differentiating benign from malignant tumors was based on the
regression of benign masses [36]. Extending serial ultrasound to include a quantitative index showed
that malignant tumors demonstrated increasing morphology index scores over time [37,39].
Others have evaluated serial CA-125 level or other biomarkers such as human epididymis protein
4 (HE4) to improve the detection of ovarian cancer [40–42]. The Risk of Ovarian Cancer Algorithm
(ROCA) is a multivariate linear model based on longitudinal data from women with ovarian cancer
and estimates intermediate and high risk for malignancy based on changes in CA-125 levels relative to
an individual’s previous levels. ROCA with multiple CA-125 determinations has performed better
in detecting ovarian cancer than a single level since CA-125 levels vary greatly depending on the
menopausal status, fertility drug use, current cigarette use, race, pelvic inflammation and irregular
menstruation [43]. Using an absolute CA-125 cut off value of 35 units/mL may result in a high false
negative rate because only 50–60% of women with stage 1 EOC will have CA-125 elevated above this
level and borderline, and Type 1 or low grade tumors are known to express low levels of CA-125 [44].
In the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOC), the largest
randomized control screening trial to date, performed between 2001–2005, 202,638 women from
the general population were assigned to a control group (no intervention) or to annual screening
using either transvaginal ultrasound (USS) or serum CA-125 interpreted by ROCA with transvaginal
ultrasound as a second line test (multimodal screening, MMS) [12,35,44]. The stage distribution of
the screen-detected primary invasive cancers was similar in both the multimodality group and the
group that received only ultrasonography [35]. In addition, 50% of primary invasive ovarian and tubal
malignancies detected by serial ultrasound screening alone had stage I or II disease versus 26% in the
control cases detected clinically (i.e., without screening) [35]. Screening produced a significant increase
in the detection of early stage ovarian malignancy. A report on the survival benefit from the UKCTOCS
has been published, which showed that, when prevalent cases were excluded, a significant mortality
reduction was noted after 7–14 years within the multimodality arm [35]. Similar but lesser mortality
reduction was seen with ultrasound alone. The trial is currently undergoing additional follow up
to further examine mortality reduction. Based on these data, it was concluded that 641 screens are
needed to prevent one ovarian cancer death [35].
Recently, it has been reported that ovarian cancer screening detects more indolent and less
aggressive Type 1 cancers [45] and that the frequency of Type 2 cancer is ~75% is higher than Type 1
with higher mortality rate for Type 2 cancer due to its faster rate of growth and metastasis. This result
is in contrast to findings from the Kentucky Ovarian Cancer Screening trial where 83.3% of early stage
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malignancies were aggressive Type 2 cancers [5,35,36,38]. In the UKCTOC ultrasound arm trial, both
Type 1 and Type 2 cancers were detected albeit more Type 1 than Type 2 [35]. Of the 23 Type 2 cancers
diagnosed in the UKCTOC ultrasound arm, 15 were associated with adnexal abnormalities, while eight
had normal ultrasound with subsequent diagnosis of ovarian cancer within 16 months (ranging 6–13
months with median of 10) [12]. No women with persisting normal ultrasound results were found to
have Type 1 ovarian cancers of the 32 women with Type 1 cancer who were detected by ultrasound in
the ultrasound arm of the UKCTOC [12]. Based on these observations, it may be concluded that many
Type 2 cancers are found in women brought to clinical practice by symptoms and that Type 2 cancers
have been shown to be quite possible to find through ovarian cancer screening using ultrasonography.
Therefore, serial ultrasound follow up of persistent masses may benefit women in clinical practice
by discriminating lethal Type 2 ovarian cancers as well as by reducing unnecessary surgery in cases
where complexity moderates or abnormalities resolve.
2.2. Can Type 2 Ovarian Cancers Be Detected by Ultrasound?
Using a growth model of serous cystadenocarcinoma (Type 2) based on retrospective analysis of
BRCA1 carriers who had undergone prophylactic bilateral salpingo-oophorectomies (PBSOs), it was
noted that high grade serous carcinoma likely spends approximately 4.3 years as histopathologically
detectable but clinically occult early stage tumors [46]. This analysis also stated that more than 50%
of serous carcinomas advanced to stage III/IV by the time they reached 3 cm in diameter. Assuming
spherical shape, this would be a volume of 14 cm3 (note that the normal ovary is 10–20 cm3 and a
walnut is 22 cm3). The report postulated that the tumor would double in volume every two and a half
months so that, at best, ultrasound follow up may only lead to the detection of low volume high grade
Type 2 cancers rather than early stage cases. However, early stage disease detected in the Kentucky
Ovarian Screening Program was larger than postulated by this model (Stage I Type 2: 65.4 cm3 ± 27.6,
27, 4.1, 366, n = 13; Stage II Type 2: 131.1 cm3 ± 33.4, 95.8, 10, 351.4, n = 14 (mean ± SEM, median,
min, max)) [5,37]. Thus, the prediction made by the model [46] that to achieve 50% sensitivity in
detecting tumors before they advance to Stage III, an annual screen would need to detect tumors of
1.3 cm in diameter is inaccurate and not supported by empirical screening data. Other investigators
modeling the levels of CA-125 associated with the smallest progressing ovarian cancers reported that
these cancers could develop unnoticed for 10.1 years and presented the view that the largest tumor
below the resolution of ultrasound (0.5 cm diameter) could progress to a detectable size (1.2–2.5 cm)
in 1–2 years [47]. Based on this estimation [47] and the Kentucky findings summarized above, early
stage Type 2 ovarian malignancies are well within the range of discovery by ultrasound. In the context
of surveillance monitoring, it would seem that arbitrary cessation as suggested by one retrospective
study [48] of ultrasound follow up of small complex adnexal masses, which are less than 6 cm at seven
months would miss both small volume high grade Type 2 cancers and the indolent Type 1 tumors that
can potentially progress to higher grade invasive cancer.
3. Risk of Ovarian Cancer When There Is an Adnexal Mass
Adapting the information from these prospective ovarian cancer screening trials to non-screening
applications in day-to-day clinical practice needs consideration. The USPSTF has recommended against
ultrasound exams for ovarian cancer screen in asymptomatic women [7] based on prior randomized
prospective ovarian cancer trials that failed to show mortality benefits while focusing on the risk of
unnecessary surgery with a small immediate complication rate or more long-term effects of premature
menopause from oophorectomy such as bone density loss. However, women present clinically with a
wide variety of indications including nonspecific symptoms, as well as more gynecologic symptoms
such as vaginal bleeding, pelvic fullness or pain. Sometimes, women may be referred for follow up
ultrasound on incidental abnormal findings from other diagnostic radiology exams such as CT that
have been obtained for unrelated reasons. Women who had any adnexal mass had a much higher
relative risk of developing ovarian cancer as observed in the UKCTOC trial, compared to women who
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had no adnexal mass [12]. The relative risk ratio for all EOC (Types 1 and 2) was 49.2 for women with
a multilocular solid cyst and 38.4 for women with a solid mass when compared to women with normal
ultrasound exams [12]. For the most deadly and aggressive ovarian cancers (Type 2), the relative risk
was 31.3 for women with a multilocular cysts with solid components and 38.4 for women with a solid
mass [12].
Even benign appearing unilocular and multilocular cysts without any solid elements have been
reported to be associated with epithelial ovarian cancer. In the UKCTOC report, unilocular and
multilocular cysts without any solid components had a relative risk for EOC within three years of
5.3 (95% CI (confidence interval) 1.9–15.2) and 6.8 (95% CI 1.9–22.9), respectively, compared to normal
ultrasound exams [12]. Among the primary EOC detected in the UKCTOC ultrasound screening
trial, 16% (nine out of 55) developed from unilocular cysts while 9% (five out of 55) developed
from multilocular cysts within three years of an initial scan. Among the borderline tumor and
Type 1 epithelial cancers, 16% (five out of 32) developed from unilocular cysts while 13% (four out
of 32) developed from multilocular cysts [12]. In another series by a separate research group, 11%
(4/35) of borderline tumors and 4% (1/24) of epithelial ovarian cancers were classified as unilocular
cysts at ultrasound examination performed by an ultrasound expert in a tertiary referral center for
gynecological ultrasound [49].
Valentin et al. noted in their cohort that the overall malignancy rate for unilocular cysts was 1%
and was higher among postmenopausal women (2.76%) then premenopausal women (0.54%) [50].
While the rates were very low, the difference was statistically significant between the two age groups.
The authors of the study noted that, upon pathologic inspection, seven of the 11 malignant cysts
described as unilocular on ultrasounds were found to contain small papillary projections or solid
components, which were not observed sonographically [50]. Careful scrutiny of ultrasound images
was advocated because subjective error or ultrasound resolution may provide explanations for the
failure to observe the papillary projections. While there are limitations to ultrasound, the degree to
which these limitations contribute to ultrasound results is small as shown by high sensitivities (>80%)
and high negative predictive values (>99%) [5,37,38].
3.1. The Risk Profile for Abnormal Ultrasound Findings
Among postmenopausal women in the general US population, the overall risk of ovarian cancer
rises with age to a 9–13% lifetime risk [51]. Relative risk increases when symptoms are present for
which a pelvic ultrasound is often performed in clinical practice, mostly because of pelvic pain. The
great majority of women with symptoms alone do not have an ovarian malignancy. The majority of
women with both symptoms and an ovarian abnormality on ultrasound also do not have a malignancy
due to the low prevalence of ovarian cancer; however, women with symptoms have been found to
have a higher prevalence of ovarian cancer than that reported for asymptomatic women in screening
trials using ultrasonography [52–54]. Differences between screening trial pelvic ultrasound outcomes
and those in clinical settings result because symptoms predominate in clinical settings.
3.2. Benefit of Serial Ultrasound Follow-Up
Serial ultrasound and a subsequent increase in morphologic complexity of an adnexal mass have
been used as the basis for surgical decisions in the single arm trial at the University of Kentucky [37]
and in the UKCTOC [35]. In the University of Kentucky trial, the majority of ovarian abnormalities
resolved within a year with serial ultrasound, including indeterminate masses. More than half of
women (63%) with ovarian cystic abnormalities had resolution in the subsequent follow-up with near
exponential resolution of ovarian abnormalities so that, by 1–2 years, only a fraction of the ovarian
abnormalities persisted (Figure 1, from [36]).
Ovarian abnormalities that continue to persist comprise only a fraction of the ovarian
abnormalities that are identified and are candidates for ongoing serial observation until their
indeterminate status changes due to an increase in morphologic complexity. Therefore, serial
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ultrasound surveillance can mitigate the potential risk from surgical complications due to prematurely
resecting indeterminate adnexal masses, especially if an adnexal mass demonstrates signs of resolving.
Ultrasound follow-up is advantageous because it is cost effective and low risk. The cost of ultrasound
follow-up is nominal compared to the cost of surgical treatment for women [55] and provides a greater
margin of safety than dismissing an extant adnexal mass without follow-up based on presuming
benign status due to an initial indeterminate ultrasound morphology.
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ovarian ultrasound abnormalities as judged by the 95% CI (Figure 2). Even allowing the 0.001% ARL
to be relaxed 10 fold would still lead to the expectation of a considerable number of extra malignancies
within three years of the first scan. If prematurely stopping surveillance caused 50% or more of these
malignancies to be diagnosed at an advanced stage, likely destined to be fatal, then extra deaths due
to curtailing surveillance can be expected to be high and emphasizes the peril of limiting ultrasound
surveillance [13].
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ovarian cancer within three years after an ultrasound exam. Data were c llected in the Unite Kingdom
Collaborative Trial of Ovarian Cancer Screening Pr tocols as published [12] and normalized by the
acceptable level of risk of no more than one extra death per 100,000 in environmental studies. Absolute
risk of subsequent malignancy is shown by the bar labeled with each type of finding on the first
ultrasound exam. The 95% confidence interval extends upward from each bar. The dashed line
indicates the 95% confidence interval of the normal ovary extended across all types of findings.
4.2. The Conundrum of Ultrasound: Subjectivity and Technical Considerations
Subjectivity and operator-depend nt errors are intrinsic to ultrasound imaging ev n when the
images are acquired and interpreted by expert radiologists or gynecologists and contain subtle features
that can go unreported or be missed. While the term expert sonographer is in wide use, there is no
definition that provides an understanding of this status or terminology. Ultrasounds are very often
performed by technologists whose varying skills and expertise are acquired and honed in the practice
in which they are employed. For experts and technologists alike, small lesions can be missed due
to various technical factors such as subject motion, lack of patient cooperation, large body habitus
with poor acoustic penetration, bowel gas shadowing which obscures pelvic organs, positioning of
the ovarian structure behind the ut rus, etc. For some large masses, complete visualization of the
wall and internal morphology cannot be obtained because the signal from the transvaginal probe
cannot adequately reach the entire mass. When this is the case, the SRU recommendations advocate
pelvic magnetic resonance images (MRIs) for better characterization and full visualization of large
masses [14]. Small papillary projec i ns withi unil cular cy ts can be absent on ultrasound, but later
confirmed by surgical pathology. Thus, there can be situations where information from ultrasound can
be inadequate.
Although ultrasound is highly sensitive, subjectivity inherent to the interpretation of ultrasound
images accounts for variation in ultrasound reports especially for indeterminate adnexal masses.
Recently, the International Ovarian Tumor Analysis (IOTA) study showed that there is considerable
uncertainly and inter-observer disagreement when solid components and papillary projection were
present [57]. Most disagreement was on the definition of a papillary projection, but there was also
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uncertainty leading to disagreement about whether a certain structure should be classified as a solid
component or as a collection of septa, a collection of small cysts or as ovarian stroma. Including
Doppler imaging can introduce variability because some septa can only be visualized with Doppler
and, therefore it can change the type of morphology that is reported.
In addition to physiological cysts, serous and mucinous cystadenomas, transitional and germ
cell tumors, struma ovarii, stromal cell tumors, fibromas, endometriomas, low malignant potential
(borderline) tumors, and malignancies, and other structures that are expected to have the potential to be
reported as having solid components in ultrasound exams of the adnexa include: inflammations,
infections and abscesses. Only after surgery has been performed is it possible to establish the
histopathologic identity of an ovarian abnormality seen on ultrasound. Histopathological identification
is not a possibility in serial ultrasound surveillance when solid structures resolve as has been reported
in the Kentucky study [36]. In brief, this study reported that while cysts with solid components had
the highest risk for epithelial ovarian cancer, many complex abnormalities (cysts with apparent solid
areas) and apparent solid masses were more likely to resolve within a year of surveillance (76.5–80.6%)
than unilocular cysts and cysts with septations (32.8–43.9%, p < 0.001) [36]. Complex abnormalities
and solid masses had a median time to resolution of 7.8–8.7 weeks, while unilocular cysts and cysts
with septations had a median time to resolution of 53–55.6 weeks. The expectation is that if these were
truly solid masses that are highly suspicious for cancer, they should not resolve. There are several
possibilities to explain this observation. First, something other than the ovary was measured in the
ultrasound report (i.e., overlapping adjacent tissue like a bowel loop). Second, the plane through which
a partially solid ovarian structure was sonographically examined exaggerated the extent to which
the structure appeared to be solid. Third, unverified factors like inflammation, infection or abscess
were responsible for reporting solid areas in the ultrasound report, providing pseudo-findings. Serial
ultrasonography provides a protection against a pseudo-finding of solid structure whenever there is
evidence of a resolving process or resolution. Few would argue that uncertainty can be eliminated
in ultrasound exams, especially with subjective interpretation providing the foundation for what is
reported. The degree to which subjective interpretation can account for the identification of apparently
“solid components” that subsequently resolve is not presently known, but can be corrected by a serial
ultrasound imaging approach in diagnostic imaging. Moreover, the utilization of complementary
Doppler imaging could contribute to differentiating a truly solid mass as distinct from a mass of clotted
blood. However, even with Doppler imaging, not all solid masses will be able to demonstrate Doppler
flow if there is too much tissue for the ultrasound beam to penetrate or if certain tumors are not
sufficiently vascularized for detection by Doppler imaging. Thus, in the absence of definitive Doppler
identification, the best solution for distinguishing apparently solid components is serial ultrasonography.
5. Ovarian Mass Ultrasound Morphology
There is considerable overlap between the ultrasonographic morphology of ovarian masses.
In the UKCTOCS study, 25 (78.1%) of the borderline/Type 1 cancers had adnexal abnormalities with
solid elements (unilocular solid/multilocular solid cysts or solid masses) on the initial (n = 23) or
subsequent (n = 2) scans [12]. Of the 23 women diagnosed with Type 2 EOC, 15 had sonographic
adnexal abnormalities where eleven (47.8%) had solid elements or ascites on the initial scan [12]. While
in the UKCTOCS study, the strongest association between ovarian morphology and epithelial ovarian
cancer was the presence of “solid component(s)”, borderline, and Type 1 and Type 2 cancers were
found across all sonographic morphologies including unilocular and multilocular cysts without solid
components. In contrast, benign pathology was the norm for all morphologies including cysts with solid
components [36]. The challenge for radiologists and gynecologic oncologists is correctly diagnosing
epithelial ovarian cancers associated with indeterminate masses having multiple thick septations and
or solid components that can be seen across borderline, indolent Type 1 tumors, aggressive Type 2
tumors and benign masses. This challenge is complicated by the low prevalence of ovarian cancer. Clear
expressions of ovarian abnormalities seen ultrasonographically are presented in Figure 3. Tumors of low
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malignant potential (i.e., borderline tumors) account for 15% of all epithelial ovarian cancers (Figure 3A).
Nearly 75% of these tumors are stage I at the time of diagnosis. They represent a heterogeneous
group and occur in younger women with favorable prognosis. However, symptomatic recurrence
and death may be found as long as 20 years after therapy in some patients. While low grade serous
tumors (Type 1) occur less frequently, pernicious high-grade serous carcinomas (Type 2) predominate,
accounting for over half of ovarian malignancies, Figure 3B. Undifferentiated carcinomas (Figure 3C,
2%), malignant mixed mesodermal tumors (Figure 3D, 3%) and high grade transitional cell carcinomas
(Figure 3E, 2%) (all Type 2) each carry a serious prognosis, but together account for less than 10%
of ovarian malignancies. Endometriod carcinomas comprise ~20% of ovarian malignancies with
low and high grade endometriod carcinomas appearing ultrasonographically similar (Figure 3F,G).
Together with clear cell carcinomas (Figure 3H, 3%), malignant Brenner’s tumor (Figure 3I, <1%) and
mucinous carcinomas (Figure 3J,K, 5%) are recognized as being responsive to treatment. Overlapping
morphological components characterize all of these tumors. To discriminate malignant from benign
abnormalities, a Morphology Index (MI) has been developed at the University of Kentucky [58]. The MI
grades an abnormality on the basis of both size and structure (morphology) as shown in Figure 4.
Increasing MI scores correlate well with the risk of an abnormality being malignant [39].Diagnostics 2017, 7, 25 11 of 19 
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Figure 3. Ultrasonographic appearance of borderline, Type 1 and Type 2 ovarian cancers. (A) Bilateral
Serous Borderline Tumor: tumors of low malignant potential (i.e., borderline tumors) account for 15%
of all epithelial ovarian cancers. Nearly 75% of these tumors are stage I at the time of diagnosis. They
represent a heterogeneous group and occur in younger women with favorable prognosis. However,
symptomatic recurrence and death may be found as long as 20 years after therapy in some patients.
(B) High Grade Serous Carcinoma (Type 2): serous carcinomas comprise the majority of ovarian
carcinomas. Unlike low-grade serous carcinoma, TP53 mutation occurs in up to 80% of high-grade
tumors [17,20]. (C) Undifferentiated Carcinoma (Type 2): about 5% of ovarian cancers are so poorly
differentiated and difficult to classify that they are called undifferentiated carcinomas and occur as
large, solid hemorrhagic structures with necrosis. (D) Malignant Mixed Mesodermal Tumor (Type 2):
occur almost exclusively in postmenopausal women. (E) High grade transitional cell carcinoma (Type 2)
is probably not a distinct entity but a poorly differentiated form of serous or endometrioid carcinoma.
(F) Low Grade Endometrioid Carcinoma (Type 1): endometriosis a likely precursor of endometrioid
carcinoma. (G) High grade Endometriod carcinoma (Type 2) is morphologically indistinguishable from
high grade serous carcinoma. (H) Clear Cell Carcinoma (Type 1): as with endometrioid carcinomas,
there is a close association between endometriosis and clear cell carcinoma. (I) Malignant Brenner
Tumor (Type 1): relatively uncommon neoplasm. Most Brenner tumors are benign, only 2–5% being
malignant. (J) Mucinous Borderline Tumor (Type 1): 53.3% of borderline tumors are serous tumors and
42.5% are mucinous tumors (42.5%). (K) Mucinous Carcinoma (Type 1): frequently has a heterogeneous
composition with coexisting elements of cystadenoma, stromal microinvasion, noninvasive carcinoma,
and invasive carcinoma.
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5.1. Malignant Degeneration of Benign Masses
It is well known that epithelial ovarian carcinomas can develop from ovarian
endometriosis [59–63]. The strongest association is seen with endometrioid and clear cell
carcinomas [64–66], which have been reported to be associated with ovarian endometriosis in
30–40% and 40–70% of cases, respectively [66,67]. Endometrioid cancer is considered as a Type 1
tumor while clear cell carcinoma is a more intermediate type [16]. Twenty-eight per cent of benign and
38% of borderline endometrioid tumors were reported to be associated with endometriosis in one
series [68,69]. Thus, there are benign entities that can become malignant.
5.2. Psychosocial Elements in Prospective Ovarian Cancer Screening Trials
In an age when patients can freely review their medical charts, including their entire radiology
report, and access the Internet for information, we enter uncharted territory in how to communicate
our findings with patients. The cost in following an ovarian mass by ultrasound is nominal compared
to surgery or extensive chemo-radiation treatment when ovarian cancer is detected at a later stage.
When women were polled about screening for ovarian cancer by the University of Kentucky Ovarian
Cancer trial team, 97% of the women surveyed reported that they wanted to be screened and that they
would even pay for screening themselves because ovarian cancer has a mortality ratio that is four times
greater than breast cancer, despite an incidence rate that is low [70] even with potential complications
that range from long-term physiological changes such as bone density loss to surgical mortality.
It is legitimate to consider if serial ultrasound and surveillance impacts psychosocial well-being.
Non-physical or psychological harm to women has been examined in the Kentucky Ovarian Screening
trial. When compared to an age and education matched group with no history of ovarian screening,
women in the Kentucky trial had more ovarian cancer-specific distress/anxiety, less optimism, and less
knowledge about risk factors upon entry [71]. Thus, some distress or anxiety relative to ovarian cancer
appears to play a motivating role for entering the Kentucky screening trial. As part of these efforts,
the validity of self-reporting by women in the Kentucky trial was evaluated and found to be very
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high [72]. In a study with baseline, two-week and four-month measurement, recipients of a normal
ovarian screening exam showed decreased ovarian cancer-related distress, increased positive effects
and increased knowledge of risk factors [73], indicating, for the vast majority of women screened, that
there are beneficial effects on ovarian cancer-specific anxiety, attitude and knowledge. Women who
received an abnormal TVS screening result were found to have an elevated ovarian cancer-specific
distress (but not general distress) at a two-week follow-up that returned to baseline at the four-month
follow-up [74]. Results were influenced by a monitoring coping style, low optimism and family
history of ovarian cancer. Needs that have been identified in women with an abnormal TVS screening
result deal with anticipation, emotional responses, role of the sonographer and impact of prior cancer
experiences [75]. In examining social cognitive processing vs. cognitive social health processing after
an abnormal TVS screening, analyses found that greater distress was associated with greater social
constraint [76]. Thus, psychological conditions that are apparently associated with ovarian screening
are governed by different underlying factors in different women and not the screening result per se.
Furthermore, recent published findings from the UKCTOCS data showed that screening does not
necessarily provoke an unacceptable level of anxiety or psychological morbidity [77]. Taken together,
these results support the position that surveillance and serial ultrasonography may not negatively
impact perceptions of well-being, particularly if more women were made aware that some tumors
may be low grade and slow growing.
6. Executive Summary of What We Already Know
There has been significant advancement in our understanding of ovarian cancer since the first
randomized prospective ovarian cancer screen trials were initiated to detect cancers in early stages to
reduce the mortality of this disease. We now know that ovarian cancer is a large heterogeneous group
consisting of Type 1 (indolent and low grade tumor) and Type 2 (aggressive and high grade tumor)
based on molecular, genetic make-up of the cancer and how they progress based on their precursors
or genetic predisposition [16–32]. The evidence indicates that surgical treatment based on limited
imaging or tumor marker data based on single or short-term exams has led to unnecessary surgery
with potential for morbidity or mortality [34]. Ultrasounds in ovarian cancer screening have detected
both Type 1 and Type 2 cancers even at early stages [5,12,35–38]. Because benign and malignant
ovarian neoplasms share overlapping ultrasound morphologies, accounting for a high ratio of benign
to malignant surgical findings and because ovarian cancer prevalence is low while the prevalence of
ovarian abnormalities is high, active ultrasonographic surveillance of ovarian abnormalities based
on the morphologic index provides the best means for detecting Type 2 ovarian cancers. Theoretical
modeling on how Type 2 cancers behave has shown that it may be possible to detect low volume
high grade cancer with better outcomes utilizing close follow-up with ultrasounds [46,47]. Ovarian
cancer screening with ultrasound has detected a stage shift that finds malignancies at an earlier stage
and serial ultrasound has increased the positive predictive value of this approach while decreasing
false positive cases [5,36–38]. Medical-legal risk may enter the consideration when an indeterminate
mass is not followed, often leading to surgery that proves unnecessary. Unnecessary surgery on false
positive cases can have serious immediate complication rates ranging from 2–15% [12,34], but, if serial
ultrasound indicates that the abnormality is resolving, then the need for surgery could be circumvented.
Based on a comprehensive review of the literature, it can be concluded that:
(1) there are benefits in ultrasound monitoring of persisting indeterminate masses;
(2) resolution of sonographic abnormality defines benign status;
(3) stability over time may not equate with benign status particularly for Type 1 tumors;
(4) for certain types of tumors benign lesions are precursors of malignant lesions;
(5) repeated ultrasound monitoring does not negatively impact psychosocial well-being.
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7. Conclusions
In conclusion, ultrasounds are inexpensive, associated with low morbidity, widely available,
have high sensitivity in detecting abnormalities and are free of risk in image acquisition. Decisions
for following ovarian masses detected by ultrasound in day-to-day practice differ from decisions
for annual ovarian cancer screening in asymptomatic women with normal risk. The goal of ovarian
cancer screening is to detect early stage ovarian cancer with improved mortality benefit. The role of
ultrasounds in adnexal mass management should be to increase positive predictive value of detecting
ovarian cancer to minimize unnecessary surgeries and to avoid failures to detect ovarian cancers.
Findings from ovarian cancer screening trials and advances in our understanding of ovarian cancer
pathogenesis can guide the management of adnexal masses found in clinical practice, especially
since screening studies have observed that women with ovarian masses found by ultrasounds have a
higher risk for ovarian cancer than those women who do not have an ovarian mass. Serial ultrasound
surveillance using a morphologic index allows quantitative surveillance and the ability to distinguish
benign masses based upon stable index scores (absence of growth, stable morphology) or decreasing
index scores (resolution), while increasing index scores are strongly linked to malignancy. Concomitant
use of serial CA-125 as in the ROCA model should also increase the positive predictive value of
detecting malignancy. All improvements should promote a close working relationship between
diagnostic radiology and clinicians using standardized structured reporting models as advocated by
the American College of Radiology as seen in the Breast Imaging Reporting Data System (BI-RADS)
or the Liver Imaging Reporting Data System (LI-RADS) to reduce ambiguous terminology, decrease
variability in interpretation and improve communication.
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